Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
|Videos|February 10, 2021
Employing AI and Machine Learning to Advance Process Operations
Author(s)Pharmaceutical Technology Editors
How can artificial intelligence and machine learning be used to gather and process real-time manufacturing data?
Advertisement
New technologies, such as artificial intelligence and machine learning, are being employed by bio/pharma manufacturers to collect and analyze large amounts of process data in real-time. Hear an expert panel will discuss how this technology can be employed to optimize bio/pharma manufacturing and predictive maintenance.
This Editors’ Series panel discussion, moderated by the editors of Pharmaceutical Technology and BioPharm International, features Bikash Chatterjee, CEO, Pharmatech Associates; Pamela Docherty, life sciences industry manager, Siemens; Amos Dor, general manager of the Pharma team, automation products group, Applied Materials; and Bob Lenich, global life sciences director, Emerson.
The panel discussion—Technology Advances in Process Operations: Using Real-time Montioring and Artificial Intelligence to Optimize Manufacturing Operations was recorded during the 2020 Bio/Pharma Virtual Congress on Nov. 11, 2020.
Advertisement
Related to this article
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Advertisement
Advertisement